What to expect when starting XERMELO
Many patients saw significant improvement within 12 weeks1
Some patients may start to see results within three weeks1
In the 12-week study, patients reported improvement in their diarrhea symptoms, primarily a reduction in bowel movement frequency. However, you could see results as early as three weeks.1
Continue to take XERMELO even if your symptoms improve
It’s important to continue taking XERMELO three times a day, every day. If you stop taking it, your symptoms could return, because Carcinoid Syndrome Diarrhea is a chronic condition.2
Take XERMELO three times a day, every day, with food1
XERMELO is a convenient pill that may help reduce diarrhea and the number of daily bowel movements when you take it regularly as directed.1 Also, people who take XERMELO with their SSA treatment may need fewer rescue SSA injections.1,3
Tips for taking XERMELO
- Take XERMELO three times a day, every day, with food
- Carry it with you while you’re on the go
- Set reminders on your phone, or sign up with a Clinical Nurse Educator to receive reminder text messages
- Write down reminders in a journal or planner
Get started with XERMELO
Download a brochure to learn more about starting treatment with XERMELO.
*Eligibility criteria: Eligibility cannot be determined until all of the information submission requirements have been met by the healthcare professional, patient, and/or caregiver. Patients are not eligible for co-pay assistance if prescriptions are paid by any state or other federally funded programs, including, but not limited to, Medicare, Medicaid, Medigap, VA, DOD, TriCare, or where prohibited by law.
- XERMELO Prescribing Information. Deerfield, IL: TerSera Therapeutics LLC.
- Molina-Cerrillo J, Alonso-Gordoa T, Martínez-Sáez O, Grande E. Inhibition of peripheral synthesis of serotonin as a new target in neuroendocrine tumors. Oncologist. 2016;21(6):701-707.
- Kulke MH, Hörsch D, Caplin ME, et al. Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome. J Clin Oncol. 2017;35(1):14-23.